GLP1R and diabetes mellitus: For instance, the 2019 European Society of Cardiology (ESC) guidelines for the management of T2DM, pre-diabetes, and CVD developed in collaboration with the EASD recognize the role of GLP1-RAs in reducing the risk of MACE in patients with T2DM and CVD [122].